Jump to content

MAGEA11

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Monkbot (talk | contribs) at 16:52, 1 September 2015 (→‎Further reading: Task 7c: repair/replace et al. in cs1 author/editor parameters;). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Template:PBB Melanoma-associated antigen 11 is a protein that in humans is encoded by the MAGEA11 gene.[1][2] It is also involved in the androgen and progesterone receptor signaling pathways.

MAGEA11 is an androgen coregulator specific to primates.[3] It was first identified in human melanomas, and has since been linked to several cancers.[4] It is observed on spermatogonia and primary spermatocytes, and in some prostate and breast cancers.[5]

Template:PBB Summary

Interactions

MAGEA11 has been shown to interact with TCEA2,[6] Androgen receptor[7][8] and SH2D4A.[6]

Genetics

MAGE-A genes have several noncoding exons followed by one protein-coding exon. MAGEA11 is mapped to the human chromosome X, forming a locus at q28 with other MAGE-A proteins. MAGE-A11 is located between two copies of MAGEA9 and MAGEA8, and is immediately downstream of the duplicated area. Its sublocus is about 2 Mb from the second sublocus containing the other MAGEA genes.[4]

Androgen Receptor

MAGE-A11 is part of the androgen receptor signaling pathway in humans. It binds directly to the androgen receptor, promoting transcriptional through direct binding to the androgen receptor FXXLF motif region.[3][9] This control is specific to primates, and is due to a mutation in the androgen receptor from alanine to valine at residue 33, which extends the α-helix, which enables direct MAGE-A11 binding to the androgen receptor.[3] Post-translational modification of the protein by phosphorylation of Thr-360 and monoubiquitinylation of Lys-240 and Lys-245 also stabilizes the interaction with the androgen receptor.[10] MAGE-A11 likely links transcriptionally active androgen receptor dimers.[11] The MAGE-A11 dependent increase in androgen receptor transcriptional activity is mediated by a direct interaction of MAGE-A11 and transcriptional intermediary factor 2 (TIF2), suggesting that MAGE-A11 may act as a bridging factor to recruit other androgen receptor coactivators.[10] Mutations in the androgen receptor that interfere with binding of MAGE-A11 can cause partial androgen insensitivity syndrome.[12]

Progesterone Receptor

MAGE-A11 also acts as an isoform-specific coregulator of full-length human progesterone receptor-B through an interaction with the receptor’s N terminal.[11] It increases progesterone and glucocorticoid receptor activity, resulting in greater regulatory control over activation domain dominance compared to mice.[3]

Cancer

Most MAGE-A genes are not expressed in healthy tissues except testicular, ovarian, and placental germ cells. They are expressed in tumor cells. MAGE-A11 in particular shows high expression in a small number of tumors, but low levels in all others.[13]

Breast cancers

The MAGE-A family are linked to many kinds of cancerous tumors. MAGE-A11 expression is positively associated with HER-2 expression, and increased MAGE-A11 concentrations are associated with shorter life expectancies of patients with breast cancer.[14]

Prostate cancer

Increased expression of MAGE-A11 during prostate cancer progression enhances both the androgen receptor signaling pathway and cancer growth. MAGE-A11 mRNA levels increase significantly during androgen deprivation therapy to treat prostate cancer, and MAGE-A11 levels have been found to be highest in castration-recurrent prostate cancer.[11][15] The drastic increase is the result of DNA hypomethylation of a CpG island in the 5’ promoter of the MAGE-A11 gene. Cyclic AMP has also been found to increase MAGE-A11 expression as well as androgen receptor activity in prostate cancer cell lines, and extensive DNA methylation of the promoter inhibits the effects of cAMP.[15]

References

  1. ^ Rogner UC, Wilke K, Steck E, Korn B, Poustka A (Mar 1996). "The melanoma antigen gene (MAGE) family is clustered in the chromosomal band Xq28". Genomics. 29 (3): 725–31. doi:10.1006/geno.1995.9945. PMID 8575766.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  2. ^ "Entrez Gene: MAGEA11 melanoma antigen family A, 11".
  3. ^ a b c d Lui QS, Su S, Blackwelder AJ, Minges JT, Wilson EM (2011). "Gain in transcriptional activity by primate-specific coevolution of melanoma antigen-A11 and its interaction site in androgen receptor". Journal of Biological Chemistry. 286 (34): 29951–29963. doi:10.1074/jbc.m111.244715.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  4. ^ a b Artamonova II & Gelfand MS (2004). "Evolution of the exon-intron structure and alternative splicing of the MAGE-A family of cancer/testis antigens". Journal of Molecular Evolution. 59: 620–631. doi:10.1007/s00239-004-2654-3.
  5. ^ Sang M, Lian Y, Zhou X, Shan B (2011). "MAGE-A family: Attractive targets for cancer immunotherapy". Vaccine. 29 (47): 8496–8500. doi:10.1016/j.vaccine.2011.09.014.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  6. ^ a b Rual, Jean-François (Oct 2005). "Towards a proteome-scale map of the human protein-protein interaction network". Nature. 437 (7062). England: 1173–8. doi:10.1038/nature04209. PMID 16189514. {{cite journal}}: Cite has empty unknown parameters: |laydate=, |laysummary=, and |laysource= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  7. ^ Bai, Suxia; He Bin; Wilson Elizabeth M (Feb 2005). "Melanoma Antigen Gene Protein MAGE-11 Regulates Androgen Receptor Function by Modulating the Interdomain Interaction". Mol. Cell. Biol. 25 (4). United States: 1238–57. doi:10.1128/MCB.25.4.1238-1257.2005. ISSN 0270-7306. PMC 548016. PMID 15684378. {{cite journal}}: Cite has empty unknown parameters: |laysummary=, |laydate=, and |laysource= (help)
  8. ^ Bai, Suxia; Wilson Elizabeth M (Mar 2008). "Epidermal Growth Factor-Dependent Phosphorylation and Ubiquitinylation of MAGE-11 Regulates Its Interaction with the Androgen Receptor". Mol. Cell. Biol. 28 (6). United States: 1947–63. doi:10.1128/MCB.01672-07. PMC 2268407. PMID 18212060. {{cite journal}}: Cite has empty unknown parameters: |laydate=, |laysummary=, and |laysource= (help)
  9. ^ Askew EB, Bai S, Blackwelder AJ & Wilson EM (2010). "Transcriptional synergy between melanoma antigen gene protein-a11 (MAGE-A11) and p300 in androgen receptor signalling". Journal of Biological Chemistry. 285 (28): 21824–21836. doi:10.1074/jbc.m110.120600.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  10. ^ a b Askew EB, Bai S, Hnat AT, Minges JT & Wilson EM (2009). "Melanoma antigen gene protein-A11 (MAGE-11) F-box links the androgen receptor NH2-terminal transactivation domain to p160 coactivators". The Journal of Biological Chemistry. 284 (50): 34793–34808. doi:10.1074/jbc.m109.065979.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  11. ^ a b c Minges JT, Su S, Grossman G, Blackwelder AJ, Pop EA, Mohler JL & Wilson EM (2013). "Melanoma Antigen-A11 (MAGE-A11) enhances transcriptional activity by linking androgen receptor dimers". Journal of Biological Chemistry. 288 (3): 1939–1952. doi:10.1074/jbc.m112.428409.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  12. ^ Lagarde WH, Blackwelder AJ, Minges JT, Hnat AT, Andrew T, French FS, Wilson EM (2012). "Androgen receptor exon 1 mutation causes androgen insensitivity by creating phosphorylation site and inhibiting melanoma antigen-A11 activation of NH2- and carboxyl-terminal interaction-debendent transactivation". Journal of Biological Chemistry. 287 (14): 10905–10915. doi:10.1074/jbc.m111.336081.{{cite journal}}: CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link)
  13. ^ Serrano A, Lethe B, Melroisse J, Lurquin C, De Plaen E, Brasseur F, Rimoldi D & Boon T (1999). "Quantitative evaluation of the expression of MAGE genes in tumors by limiting dilution of cDNA libraries". International Journal of Cancer. 85 (5): 664–669. doi:10.1002/(sici)1097-0215(19991126)83:5<664::aid-ijc16>3.3.co;2-m.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  14. ^ Lian Y, Sang M, Ding C, Zhou X, Fan X, Xu Y, Lu W, Shan B (2012). "Expressions of MAGE-A10 and MAGE-A11 in breast cancers and their prognostic significance: A retrospective clinical study". Journal of Cancer Research and Clinical Oncology. 138 (3): 519–527. doi:10.1007/s00432-011-1122-x.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  15. ^ a b Karpf AR, Bai S, James SR, Mohler JL & Wilson EM (2009). "Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP". Molecular Cancer Research. 7: 525–535. doi:10.1158/1541-7786.mcr-08-0400.{{cite journal}}: CS1 maint: multiple names: authors list (link)

Further reading

Template:PBB Further reading

Template:PBB Controls

Retrieved from "https://en.wikipedia.org/w/index.php?title=MAGEA11&oldid=678953213"